Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older; Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for the treatment of ADHD; and Adzenys ER, an amphetamine XR liquid suspension for the treatment of ADHD. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NEOS
CUSIPN/A
Phone972-408-1300
Debt
Debt-to-Equity Ratio-2.36
Current Ratio1.07
Quick Ratio0.84
Price-To-Earnings
Trailing P/E Ratio-2.13
Forward P/E Ratio-3.48
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.02 million
Price / Sales6.76
Cash FlowN/A
Price / CashN/A
Book Value$0.27 per share
Price / Book21.11
Profitability
EPS (Most Recent Fiscal Year)($2.68)
Net Income$-66,240,000.00
Net Margins-164.40%
Return on Equity-586.25%
Return on Assets-59.85%
Miscellaneous
Employees138
Outstanding Shares29,670,000
Market Cap$185.46 million
Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions
What is Neos Therapeutics' stock symbol?
Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."
How were Neos Therapeutics' earnings last quarter?
Neos Therapeutics Inc (NASDAQ:NEOS) posted its quarterly earnings results on Wednesday, August, 8th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.44) by $0.08. The company had revenue of $11.36 million for the quarter, compared to analysts' expectations of $11.90 million. Neos Therapeutics had a negative return on equity of 586.25% and a negative net margin of 164.40%. View Neos Therapeutics' Earnings History.
When is Neos Therapeutics' next earnings date?
What price target have analysts set for NEOS?
4 analysts have issued 12 month price targets for Neos Therapeutics' shares. Their predictions range from $11.00 to $20.00. On average, they expect Neos Therapeutics' stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 171.9% from the stock's current price. View Analyst Price Targets for Neos Therapeutics.
What is the consensus analysts' recommendation for Neos Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neos Therapeutics.
What are Wall Street analysts saying about Neos Therapeutics stock?
Here are some recent quotes from research analysts about Neos Therapeutics stock:
- 1. According to Zacks Investment Research, "Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. " (8/11/2018)
- 2. Cantor Fitzgerald analysts commented, "Positives from the quarter that support our thesis 1) On 01/10/18 NEOS announced that study findings for two of its ADHD medications, ER, were presented in three posters at the upcoming 2018 Annual Meeting of the American Professional Society of ADHD and Related Disorders (APSARD), on 02/20/18 PDL Biopharma (Not Covered) announced termination of interest in acquiring 02/26/18 NEOS announced the U.S. launch of Adzenys ER, making it NEOS’s third ADHD product launch in less than two years; 4) as discussed at the company’s analyst day in March of 2018, NEOS plans to advance its drug candidate for the treatment of nausea and vomiting into the clinic in 2H18 and to identify one additional branded product candidate in CNS or gastroenterology in 2018; and 5) as of 03/31/18 the company held $37.2MM in cash and cash equivalents." (5/9/2018)
Who are some of Neos Therapeutics' key competitors?
Some companies that are related to Neos Therapeutics include NuCana (NCNA), Inflarx (IFRX), Kura Oncology (KURA), Aptinyx (APTX), CymaBay Therapeutics (CBAY), Crinetics Pharmaceuticals (CRNX), Kiniksa Pharmaceuticals (KNSA), Epizyme (EPZM), Geron (GERN), ANI Pharmaceuticals Inc Common Stock (ANIP), Vectura Group (VEGPF), Abeona Therapeutics (ABEO), Urogen Pharma (URGN), Viking Therapeutics (VKTX) and Adamas Pharmaceuticals (ADMS).
Who are Neos Therapeutics' key executives?
Neos Therapeutics' management team includes the folowing people:
- Mr. Richard I. Eisenstadt, Chief Financial Officer (Age 60)
- Mr. Thomas P. McDonnell, Chief Commercial Officer (Age 46)
- Dr. Vipin K. Garg, Advisor (Age 60)
- Mr. Gerald W. McLaughlin, CEO & Director (Age 50)
- Mr. Russ McMahen, VP of R&D
When did Neos Therapeutics IPO?
(NEOS) raised $60 million in an IPO on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.
Has Neos Therapeutics been receiving favorable news coverage?
News headlines about NEOS stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neos Therapeutics earned a media and rumor sentiment score of 0.17 on Accern's scale. They also assigned media headlines about the company an impact score of 44.63 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for Neos Therapeutics.
Who are Neos Therapeutics' major shareholders?
Neos Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.21%), Russell Investments Group Ltd. (2.12%), Nexthera Capital LP (1.28%), Proxima Capital Management LLC (0.99%), Millennium Management LLC (0.57%) and Canada Pension Plan Investment Board (0.26%). Company insiders that own Neos Therapeutics stock include Bryant Fong and Richard I Eisenstadt. View Institutional Ownership Trends for Neos Therapeutics.
Which major investors are selling Neos Therapeutics stock?
Which major investors are buying Neos Therapeutics stock?
NEOS stock was acquired by a variety of institutional investors in the last quarter, including Nexthera Capital LP, BlackRock Inc., Millennium Management LLC, Proxima Capital Management LLC, Canada Pension Plan Investment Board, Trexquant Investment LP and Schwab Charles Investment Management Inc.. Company insiders that have bought Neos Therapeutics stock in the last two years include Bryant Fong and Richard I Eisenstadt. View Insider Buying and Selling for Neos Therapeutics.
How do I buy shares of Neos Therapeutics?
Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neos Therapeutics' stock price today?
One share of NEOS stock can currently be purchased for approximately $5.70.
How big of a company is Neos Therapeutics?
Neos Therapeutics has a market capitalization of $185.46 million and generates $25.02 million in revenue each year. The company earns $-66,240,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Neos Therapeutics employs 138 workers across the globe.
How can I contact Neos Therapeutics?
Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]
MarketBeat Community Rating for Neos Therapeutics (NASDAQ NEOS)
MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote "Outperform" if you believe NEOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
